Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Deal watch

Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs

GlycoMimetics has granted Pfizer exclusive worldwide rights to develop and commercialize GMI-1070, a rationally designed glycomimetic inhibitor of E-, L- and P-selectin, for vaso-occlusive crisis associated with sickle cell disease (SCD). Under the terms of the agreement, which could be worth up to US$340 million to GlycoMimetics, the company will remain responsible for the completion of an ongoing Phase II trial of GMI-1070, and Pfizer will then assume all further development and commercialization responsibilities.

SCD is a rare genetic disorder for which there are limited available treatments. The main clinical feature of the disease is the recurrent, painful and life-threatening vaso-occlusive crisis that occurs when the flow of blood is blocked, as sickle cells become stuck within a blood vessel. At present, treatment primarily relies on supportive therapy consisting of hydration and pain relief.

By inhibiting selectin interactions, GMI-1070 may be able to decrease leukocyte adhesion and recruitment to inflamed tissues in various disorders, such as the inflamed venules in SCD. “An adhesive interaction between the sickle red cell and the endothelium is an essential event initiating vaso-occlusion. Some evidence suggests that the sickle cell–endothelium interaction is initiated by selectins, particularly P-selectin,” explains Martin H. Steinberg (Professor of Medicine, Pediatrics, Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Massachusetts, USA). There is also evidence that E-selectin, expressed by inflamed vascular endothelial cells, activates neutrophils that capture sickle cells, promoting vaso-occlusion. “Therefore, the pan-selectin antagonist GMI-1070 represents a valuable and novel therapeutic compound for acute sickle cell crisis,” comments Beat Ernst (Professor of Molecular Pharmacy, University of Basel, Switzerland).

GMI-1070, which has been granted orphan drug and fast track status by the US Food and Drug Administration, successfully completed Phase I trials in 2009 (ClinicalTrials.gov identifier: NCT00911495) for the treatment of vaso-occlusive crisis associated with SCD. Data from a double-blind, placebo-controlled Phase II trial in 78 patients receiving standard therapy are expected next year (ClinicalTrials.gov identifier: NCT01119833).

GMI-1070 has to be given intravenously, which is not ideal when attempting to prevent vaso-occlusive events. “The best treatment approach to inhibit these cellular interactions would be to use an oral selectin inhibitor as a prophylactic,” says Steinberg. However, “developing a carbohydrate lead into an orally available mimetic that is not rapidly excreted remains a challenge”, says Ernst, and although monoclonal antibodies could also be used to target specific selectins, he adds that “one of the advantages of using a glycomimetic, such as GMI-1070, is that all three selectins can be antagonized with one compound”.

GMI-1070 is also being evaluated in preclinical studies for the treatment of other diseases in which adhesive interactions have a key role in the disease process. Recent data (abstract number 453) presented at the 2010 Annual Meeting of the American Society of Hematology demonstrated that GMI-1070 inhibits the homing of multiple myeloma cells to the bone marrow and improves the efficacy of bortezomib (Velcade; Millennium Pharmaceuticals) in animal models.

In summary, although GMI-1070 is not an oral drug and its long-term use might interfere with intercellular interactions that are vital for homeostasis, such as neutrophil migration to infected tissues, its plasma half-life and safety profile support the viability of glycomimetic drugs. As Ernst concludes: “GMI-1070 could be a door opener for other glycomimetic drugs — for example, in the field of infectious diseases or cancer.”

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov 10, 890 (2011). https://doi.org/10.1038/nrd3622

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3622

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing